PDCD1 and Miyoshi myopathy: Despite the observed low levels of PD-L1 expression in these specimens, the study revealed that anti-PD-1 treatment did not elicit clinical responses in patients, highlighting the challenges and limitations associated with checkpoint inhibitors in the treatment of advanced MM (80).